Published in J Clin Oncol on August 01, 2007
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol (2012) 2.31
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol (2010) 2.02
New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol (2008) 1.58
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58
The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int (2015) 1.50
Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol (2008) 1.41
Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol (2013) 1.31
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol (2009) 1.27
Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol (2009) 1.24
Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol (2009) 1.13
Controversies in the adjuvant therapy of high-grade gliomas. Oncologist (2011) 1.12
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol (2013) 1.07
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol (2010) 1.06
Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (2011) 1.06
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol (2012) 1.04
MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med (2012) 1.03
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Ann Oncol (2009) 1.02
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol (2016) 0.98
Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol (2012) 0.98
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol (2013) 0.96
Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol (2014) 0.94
Nonsurgical treatment of recurrent glioblastoma. Curr Oncol (2015) 0.90
Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol (2014) 0.90
Extended-schedule dose-dense temozolomide in refractory gliomas. J Neurooncol (2009) 0.90
Temozolomide in malignant glioma. Onco Targets Ther (2010) 0.89
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study. BMC Cancer (2009) 0.87
Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer (2009) 0.87
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer (2014) 0.85
Cellular-based immunotherapies for patients with glioblastoma multiforme. Clin Dev Immunol (2012) 0.84
Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival. Br J Cancer (2010) 0.82
Are we done with dose-intense temozolomide in recurrent glioblastoma? Neuro Oncol (2014) 0.82
Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them? Front Neurol (2013) 0.82
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer (2013) 0.79
Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives. Front Pediatr (2013) 0.78
Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. Neurosurgery (2016) 0.77
Retrospective analysis of bevacizumab in combination with fotemustine in chinese patients with recurrent glioblastoma multiforme. Biomed Res Int (2015) 0.76
CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro Oncol (2015) 0.76
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. BMC Cancer (2016) 0.76
Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. CNS Drugs (2017) 0.76
Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma. J Korean Neurosurg Soc (2015) 0.75
Dose-dense temozolomide: is it still promising? Neurol Med Chir (Tokyo) (2014) 0.75
Temozolomide and MGMT forever? Neuro Oncol (2010) 0.75
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Manag Res (2009) 0.75
Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncol Lett (2012) 0.75
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma. BMC Cancer (2015) 0.75
Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol (2017) 0.75
Management and treatment recommendations for World Health Organization Grade III and IV gliomas. Int J Health Sci (Qassim) (2017) 0.75
[Drug therapy of patients with recurrent glioblastoma: is there any evidence?]. Wien Med Wochenschr (2010) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
International network of cancer genome projects. Nature (2010) 20.35
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 10.99
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol (2002) 8.62
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol (2012) 6.20
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 4.63
Long-term survival with glioblastoma multiforme. Brain (2007) 4.51
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol (2009) 4.32
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol (2010) 3.88
Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med (2012) 3.67
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol (2011) 3.66
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol (2009) 3.65
Do brain tumours allow valid conclusions on the localisation of human brain functions?--Objections. Cortex (2010) 3.61
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol (2007) 3.53
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol (2014) 3.52
Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology (2015) 3.48
Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med (2008) 3.41
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol (2014) 3.21
Histological classification and molecular genetics of meningiomas. Lancet Neurol (2006) 3.19
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res (2007) 3.05
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med (2002) 3.03
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res (2008) 2.84
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol (2009) 2.67
A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain (2010) 2.49
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol (2003) 2.38
O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain (2005) 2.37
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn (2007) 2.35
Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol (2011) 2.31
Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol (2012) 2.31
EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell (2013) 2.28
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 2.27
Current concepts and management of glioblastoma. Ann Neurol (2011) 2.23
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol (2012) 2.17
Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica? Pain (2010) 2.09
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem (2006) 2.08
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology (2014) 2.02
Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol (2005) 2.00
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res (2012) 1.98
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology (2013) 1.98
Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res (2008) 1.94